Cellectis CanCELL cell lines enable drug positioning in cancer pathways

Apr 11 2013

CanCELL™ cell lines are featuring gene knock-outs of the major cancer relevant oncogenes and tumor suppressor genes. This new product line answers identified market needs in oncology research and drug discovery.

CanCELL™ cell lines were generated by applying Cellectis bioresearch proprietary TALEN™ technology on the most commonly used cell lines for colorectal and lung cancer studies. Gene selection was based on clinically validated cancer pathways and focuses on most common cancer diseases.

CanCELL™ offers unparalleled opportunities to study signaling pathways, gene function and to develop functional assays in a common genetic background. It represents a unique tool for drug positioning in cancer pathways and identification of novel personalized drugs. CanCELL™ allows the evaluation of the relationship between drug efficacy and pathway activation/ inactivation or the set-up of primary screening (siRNA, shRNA, drug candidates) to identify synthetic lethal interactions.

All CanCELL™ knock-out cell lines are derived from the same parental cell line guaranteeing true isogeny and are authenticated though STR-analysis.

Source Cellectis